Amphastar Pharmaceuticals, Inc. Long-Term Debt
Amphastar Pharmaceuticals, Inc. (AMPH) had Long-Term Debt of $619.71 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation
us-gaap:LongTermDebtNoncurrent · last filed 2026-02-26
- 2025-12-31: Long-term Debt, Excluding Current Maturities $619.71M.
- 2024-12-31: Long-term Debt, Excluding Current Maturities $613.53M.
- 2023-12-31: Long-term Debt, Excluding Current Maturities $603.17M.
- 2023-09-30: Long-term Debt, Excluding Current Maturities $653.27M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2025-12-31 | $619.71M 10-K · filed 2026-02-26 |
| 2024-12-31 | $613.53M 10-K · filed 2025-03-03 |
| 2023-12-31 | $603.17M 10-K · filed 2024-02-29 |
| 2023-09-30 | $653.27M 10-Q · filed 2023-11-08 |
| 2022-12-31 | $76.64M 10-K · filed 2023-03-01 |
| 2021-12-31 | $78.19M 10-K · filed 2022-03-11 |
| 2020-12-31 | $45.92M 10-K · filed 2021-03-15 |
| 2019-12-31 | $46.32M 10-K · filed 2020-03-16 |
| 2018-12-31 | $49.10M 10-K · filed 2019-03-15 |
| 2017-12-31 | $45.72M 10-K · filed 2018-03-14 |
| 2016-12-31 | $36.03M 10-K · filed 2017-03-15 |
| 2015-12-31 | $40.30M 10-K · filed 2016-03-15 |
| 2014-12-31 | $42.68M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |